Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.765 GBX | -7.27% | -10.00% | -10.00% |
Apr. 25 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
Apr. 23 | N4 Pharma loss widens but "great optimism" remains | AN |
Sales 2021 | - | Sales 2022 | - | Capitalization | 4.32M 5.4M |
---|---|---|---|---|---|
Net income 2021 | -1M -1.25M | Net income 2022 | -1M -1.25M | EV / Sales 2021 | - |
Net cash position 2021 | 1.78M 2.23M | Net cash position 2022 | 1.92M 2.4M | EV / Sales 2022 | - |
P/E ratio 2021 |
-5.22
x | P/E ratio 2022 |
-3.35
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.72% |
Latest transcript on N4 Pharma Plc
1 day | -7.27% | ||
1 week | -10.00% | ||
Current month | +17.69% | ||
1 month | +13.33% | ||
3 months | -12.57% | ||
6 months | -10.00% | ||
Current year | -10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 13-12-31 | |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 17-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 46 | 20-07-13 | |
Founder | 59 | 13-12-31 | |
Chris Britten
CHM | Chairman | - | 19-05-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.765 | -7.27% | 511 200 |
24-04-25 | 0.825 | 0.00% | 3,285,001 |
24-04-24 | 0.825 | -2.94% | 823,510 |
24-04-23 | 0.85 | 0.00% | 4,804,558 |
24-04-22 | 0.85 | 0.00% | 849,442 |
Delayed Quote London S.E., April 26, 2024 at 10:03 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-10.00% | 2.77M | |
+26.14% | 653B | |
+26.39% | 556B | |
-6.52% | 354B | |
+20.38% | 331B | |
+5.38% | 296B | |
+12.68% | 233B | |
+5.54% | 201B | |
-9.61% | 193B | |
-5.80% | 144B |
- Stock Market
- Equities
- ONZ Stock